H-EVDPIGHLY-OH
Ref. 3D-PP46939
1mg | 217,00 € | ||
10mg | 253,00 € | ||
100mg | 455,00 € |
Produktinformation
- NH2-Glu-Val-Asp-Pro-Ile-Gly-His-Leu-Tyr-OH
Peptide H-EVDPIGHLY-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-EVDPIGHLY-OH include the following: Long-peptide cross-presentation by human dendritic cells occurs in vacuoles by peptide exchange on nascent MHC class I molecules W Ma, Y Zhang , N Vigneron, V Stroobant - The Journal of , 2016 - journals.aai.orghttps://journals.aai.org/jimmunol/article/196/4/1711/43276 A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful W Ma, N Vigneron, J Chapiro - journal of cancer, 2011 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.25911 Induction of human leukocyte antigen (HLA)-A2-restricted and MAGE-3-gene-derived peptide-specific cytolytic T lymphocytes using cultured dendritic cells from an S Kanaoka, S Yamasaki, T Okino - Journal of surgical , 1999 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1096-9098(199905)71:1%3C16::AID-JSO4%3E3.0.CO;2-A Electrophoresis-related protein modification: Alkylation of carboxy residues revealed by mass spectrometry S Haebel, T Albrecht, K Sparbier, P Walden - , 1998 - Wiley Online Libraryhttps://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/elps.1150190513 Chemical derivatization strategy for extending the identification of MHC class I immunopeptides R Chen , F Fauteux , S Foote, J Stupak - Analytical , 2018 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.analchem.8b02420 Tumor-specific shared antigenic peptides recognized by human T cells P Van Der Bruggen , Y Zhang , P Chaux - Immunological , 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1034/j.1600-065X.2002.18806.x Production of an antigenic peptide by insulin-degrading enzyme N Parmentier, V Stroobant, D Colau - Nature , 2010 - nature.comhttps://www.nature.com/articles/ni.1862 Facile method for screening clinical T cell receptors for off-target peptide-HLA reactivity MH Gee , X Yang , KC Garcia - BioRxiv, 2018 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/472480.abstract Analysis of the degradation mechanisms of MHC class I-presented tumor antigenic peptides by high performance liquid chromatography/electrospray ionization mass M Ayyoub, B Monsarrat, H Mazarguil - in mass spectrometry, 1998 - Wiley Online Libraryhttps://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0231(19980515)12:9%3C557::AID-RCM199%3E3.0.CO;2-D Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies KA Chianese-Bullock, ST Lewis, NE Sherman - Vaccine, 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X09000553 A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma JS Weber, FL Hua, L Spears, V Marty - Journal of , 1999 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/abstract/1999/09000/a_phase_i_trial_of_an_hla_a1_restricted_mage_3.7.aspx Peptide vaccines for cancer J Weber - Cancer investigation, 2002 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1081/CNV-120001149 HLA Photoaffinity Labeling Reveals Overlapping Binding of Homologous Melanoma-associated Gene Peptides by HLA-A1, HLA-A29, and HLA-B44 (âËâ) IF Luescher, P Romero, D Kuznetsov, D Rimoldi - Journal of Biological , 1996 - ASBMBhttps://www.jbc.org/article/S0021-9258(18)95440-2/abstract Identification of five new HLA-B* 3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating H Benlalam, B Linard, Y Guilloux - The Journal of , 2003 - journals.aai.orghttps://journals.aai.org/jimmunol/article/171/11/6283/36031 A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes ES Schultz, Y Zhang , R Knowles, J Tine - Tissue , 2001 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1034/j.1399-0039.2001.057002103.x Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. E Celis, V Tsai, C Crimi, R DeMars - Proceedings of the , 1994 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.91.6.2105 Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides DH Hsu, P Paz, G Villaflor, A Rivas - Journal of , 2003 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2003/09000/exosomes_as_a_tumor_vaccine__enhancing_potency.7.aspx Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells BJ Cameron, AB Gerry, J Dukes, JV Harper - Science translational , 2013 - science.orghttps://www.science.org/doi/abs/10.1126/scitranslmed.3006034 CrossDome: an interactive R package to predict cross-reactivity risk using immunopeptidomics databases AF Fonseca, DA Antunes - Frontiers in Immunology, 2023 - frontiersin.orghttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1142573/full Stability and CTL-activity of P40/ELA melanoma vaccine candidate A Beck , L Goetsch, T Champion, MC Bussat, JP Aubry - Biologicals, 2001 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1045105601903069 Peptides as tools and drugs for immunotherapies A Beck , C Klinguer-Hamour, MC Bussat - Journal of Peptide , 2007 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/psc.852
Chemische Eigenschaften
Technische Anfrage zu: 3D-PP46939 H-EVDPIGHLY-OH
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.